{"product_id":"usph-vrio-analysis","title":"U.S. Physical Therapy, Inc. (USPH): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to U.S. Physical Therapy, Inc. (USPH)'s sustained success by examining its core competencies through this focused VRIO Analysis. We cut straight to the chase, evaluating if its resources are truly Valuable, Rare, Inimitable, and Organized enough to secure a lasting competitive advantage. Read on to see the definitive breakdown of where U.S. Physical Therapy, Inc. (USPH) stands in the market.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e1. Extensive, Multi-State Clinic Footprint\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a national operator that has successfully navigated a highly fragmented U.S. outpatient physical therapy market. The sheer scale of U.S. Physical Therapy, Inc.’s physical presence is the core of its current competitive position, offering tangible benefits in negotiation and market coverage.\u003c\/p\u003e\n\n\u003cp\u003eAs of the third quarter end, September 30, 2025, U.S. Physical Therapy, Inc. operated or managed \u003cstrong\u003e779\u003c\/strong\u003e outpatient clinics across \u003cstrong\u003e44\u003c\/strong\u003e states. This footprint generated Trailing Twelve Months (TTM) revenue of approximately \u003cstrong\u003e$758.71 million\u003c\/strong\u003e. That's a lot of doors open for business. The Q3 2025 net revenue from physical therapy operations alone hit \u003cstrong\u003e$168.1 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eVRIO Assessment: Clinic Footprint\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on how this footprint stacks up using the VRIO framework. This structure helps us see where the real, durable advantage lies.\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCompetitive Implication\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes. Drives economies of scale and significant payor negotiation leverage.\u003c\/td\u003e\n    \u003ctd\u003eCompetitive Parity to Temporary Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes. Few competitors match this specific breadth across \u003cstrong\u003e44\u003c\/strong\u003e states.\u003c\/td\u003e\n    \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eHigh. Organic build-out requires massive capital and over a decade of work.\u003c\/td\u003e\n    \u003ctd\u003ePotential Sustained Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eStrong. Evidenced by adding \u003cstrong\u003e84\u003c\/strong\u003e net owned clinics since Q3 2024.\u003c\/td\u003e\n    \u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch4\u003eValue: Scale for Negotiation and Reach\u003c\/h4\u003e\n\u003cp\u003eThis extensive footprint is definitely valuable. It allows U.S. Physical Therapy, Inc. to negotiate better terms with major insurance payors, something smaller, regional players struggle to achieve. Also, having clinics in \u003cstrong\u003e44\u003c\/strong\u003e states means they capture a wider slice of the total addressable market, which is key in this fragmented sector. This scale helps absorb fixed corporate costs, like compliance and IT, across a larger revenue base. If onboarding takes 14+ days, churn risk rises, but their scale helps streamline that process.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDrives economies of scale in procurement.\u003c\/li\u003e\n\u003cli\u003eBroadens leverage in payor contract discussions.\u003c\/li\u003e\n\u003cli\u003eCaptures market share across diverse geographies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch4\u003eRarity: Geographic Breadth is Uncommon\u003c\/h4\u003e\n\u003cp\u003eWhile scale exists in the rehab space - Select Medical is a proxy for a larger operator - U.S. Physical Therapy, Inc.’s specific, deep penetration across \u003cstrong\u003e44\u003c\/strong\u003e states is rare for a pure-play outpatient provider. This isn't just about having many clinics; it's about the geographic diversification that buffers against localized reimbursement changes or market saturation. It’s a tough footprint to replicate quickly.\u003c\/p\u003e\n\n\u003ch4\u003eInimitability: Time and Capital Barrier\u003c\/h4\u003e\n\u003cp\u003eBuilding this network organically is incredibly difficult. It requires decades of relationship-building with local therapists and significant, sustained capital deployment for acquisitions. What this estimate hides is the difficulty in acquiring practices that fit their partnership model, which adds another layer of inimitability beyond just the physical real estate.\u003c\/p\u003e\n\n\u003ch4\u003eOrganization: Integration Capability\u003c\/h4\u003e\n\u003cp\u003eThe organization is set up to exploit this footprint. The consistent acquisition strategy, shown by the addition of \u003cstrong\u003e84\u003c\/strong\u003e net owned clinics since the third quarter of 2024, proves the centralized support structure can effectively integrate new locations. They have the processes in place to handle the legal, HR, and revenue cycle management for this large, dispersed group. This operational readiness turns the asset (the footprint) into a realized advantage.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e2. Dual Revenue Stream: Outpatient PT and IIP Services\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Diversifies risk away from pure reimbursement pressure, as the Industrial Injury Prevention (IIP) segment grew revenue by \u003cstrong\u003e22.6%\u003c\/strong\u003e year-over-year in Q2 2025. This segment also focuses on higher-margin workers' compensation cases.\u003c\/p\u003e\n\u003cp\u003eThe dual stream provides a financial buffer against outpatient reimbursement challenges, such as the approximate \u003cstrong\u003e2.9%\u003c\/strong\u003e Medicare rate reduction effective January 1, 2025, which USPH partially offset with a net rate per patient visit of \u003cstrong\u003e$105.33\u003c\/strong\u003e in Q2 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eOutpatient PT\u003c\/td\u003e\n\u003ctd\u003eIIP Services\u003c\/td\u003e\n\u003ctd\u003eTotal Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$168.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$29.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$197.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY Revenue Growth (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eImplied lower than total\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderately rare. Many competitors focus solely on traditional outpatient care; the integrated, scaled IIP offering is less common. USPH operated \u003cstrong\u003e768\u003c\/strong\u003e owned and\/or managed clinics as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Temporary. Competitors can build or acquire IIP capabilities, but USPH has a head start and established client relationships.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Very strong. Management explicitly highlights IIP growth as a key driver offsetting Medicare rate cuts, showing clear strategic alignment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement raised full-year 2025 Adjusted EBITDA guidance to a range of \u003cstrong\u003e$93.0 million\u003c\/strong\u003e to \u003cstrong\u003e$97.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIIP Gross Profit increased by \u003cstrong\u003e25.8%\u003c\/strong\u003e year-over-year in Q2 2025 to \u003cstrong\u003e$6.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. It provides an immediate buffer, but others are moving into this space.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e3. Proven, Disciplined Acquisition and Partnership Model\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Allows for rapid, accretive growth by acquiring existing practices, which is crucial in a fragmented market ripe for consolidation.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe model supports immediate revenue and visit scale addition through transactions such as the August 2025 acquisition of a three-clinic practice generating approximately \u003cstrong\u003e$5.3 million\u003c\/strong\u003e in annual revenues and 28,000 in annual visits. The company's scale as of August 1, 2025, was 774 outpatient physical therapy clinics in 44 states.\u003c\/p\u003e\n\u003cp\u003eOperational metrics demonstrate the value capture from existing and new clinics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal patient visits for Q2 2025 were 1,558,756, a 16.7% increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eAverage daily patient visits per clinic (excluding home-care) reached an all-time high of 32.7 for Q2 2025, up from 30.6 in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eNet rate per patient visit increased to $105.33 in Q2 2025 from $105.05 in Q2 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eRecent acquisition activity includes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAcquisition Date\u003c\/th\u003e\n\u003cth\u003eType\/Size\u003c\/th\u003e\n\u003cth\u003eAcquired Interest\u003c\/th\u003e\n\u003cth\u003eAnnual Revenue (Approx.)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAugust 2025\u003c\/td\u003e\n\u003ctd\u003eThree-Clinic Practice\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovember 30, 2024\u003c\/td\u003e\n\u003ctd\u003eEight-Clinic Practice\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOctober 31, 2024\u003c\/td\u003e\n\u003ctd\u003eMSO serving \u003cstrong\u003e50\u003c\/strong\u003e Clinics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$64.0 million\u003c\/strong\u003e (Consolidated)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAugust 31, 2024\u003c\/td\u003e\n\u003ctd\u003eEight-Clinic Practice\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarch 29, 2024\u003c\/td\u003e\n\u003ctd\u003eNine-Clinic Practice\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe MSO acquisition on October 31, 2024, generated approximately \u003cstrong\u003e$12.0 million\u003c\/strong\u003e in annual EBITDA on a consolidated basis.\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe consistency and scale of deal flow, often utilizing a minority stake initial partnership structure, is moderately rare. For example, the August 2025 deal involved a 60% acquisition with owners retaining 40%. The November 30, 2024, deal involved a 75% acquisition with owners retaining 25%.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eReplicating the model requires deep industry relationships, a trusted brand for clinic founders, and a repeatable integration process. The August 31, 2024, eight-clinic acquisition had a 70% purchase price of approximately $2.0 million for the equity interest. The maximum contingent consideration for that deal was $3.6 million.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eEffective operational onboarding is suggested by sustained growth metrics. For the nine months ended September 30, 2025, total patient visits were 4,556,768, an 18.0% increase from the 3,920,388 visits in the prior year period. Adjusted EBITDA for Q2 2025 was $26.9 million, a 21.4% increase from Q2 2024.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e. The established M\u0026amp;A engine and reputation as a good partner are hard to replicate quickly. The company raised its full-year 2025 Adjusted EBITDA guidance to a range of $93.0 million to $97.0 million.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e4. Operational Efficiency and Margin Expansion Capability\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to grow Adjusted EBITDA by \u003cstrong\u003e21.4%\u003c\/strong\u003e in Q2 2025 to \u003cstrong\u003e$26.9 million\u003c\/strong\u003e while simultaneously absorbing significant Medicare rate cuts shows superior cost control. Their Q2 2025 Adjusted EBITDA margin expanded to \u003cstrong\u003e17.5%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe operational performance is quantified by the following comparative metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 2024\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA (millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Rate per Patient Visit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$105.05\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$105.33\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patient Visits\u003c\/td\u003e\n\u003ctd\u003eImplied lower than 1,558,756\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,558,756\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eTotal revenue from physical therapy operations for the 2025 Second Quarter increased \u003cstrong\u003e17.3%\u003c\/strong\u003e to \u003cstrong\u003e$168.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Most peers struggled to maintain margins against the approximate \u003cstrong\u003e2.9%\u003c\/strong\u003e Medicare cut effective January 1, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This efficiency stems from disciplined cost management and likely proprietary operational systems. Key cost control data includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSalaries and related costs rose only \u003cstrong\u003e0.7%\u003c\/strong\u003e in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eSalaries and related costs per visit was \u003cstrong\u003e$60.08\u003c\/strong\u003e for the 2025 Second Quarter compared to \u003cstrong\u003e$59.66\u003c\/strong\u003e for the 2024 Second Quarter.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Very strong. Management is clearly focused on driving efficiency per visit, which is a core operational mandate. This focus is evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManagement raising full-year 2025 Adjusted EBITDA guidance to a range of \u003cstrong\u003e$93.0 million to $97.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Industrial Injury Prevention (IIP) segment revenue grew \u003cstrong\u003e22.6%\u003c\/strong\u003e year-over-year in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eNet Income attributable to USPH's shareholders was \u003cstrong\u003e$12.4 million\u003c\/strong\u003e for Q2 2025, up from \u003cstrong\u003e$7.5 million\u003c\/strong\u003e for Q2 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This operational muscle is what separates leaders from laggards when facing regulatory headwinds.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e5. Brand Trust Among Clinic Founders\/Partners\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Attracts high-quality, established physical therapy practices looking to partner or sell, ensuring a steady pipeline of revenue-generating assets. This is key to their growth strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: High. In a professional services model like this, the trust of the local practitioners is a non-financial asset that takes years to build.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Very High. Competitors cannot simply buy this trust; it is earned through consistent treatment of existing partners.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Strong. The partnership structure, where founders often retain a minority stake, is designed to maintain this trust.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained. This social capital is a powerful barrier to entry for new consolidators.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Date Reference\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Owned\/Managed Clinics\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e774\u003c\/strong\u003e Clinics\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeographic Footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e44\u003c\/strong\u003e States\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFounder Equity Retention Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~20% to 40%\u003c\/strong\u003e Retained\u003c\/td\u003e\n\u003ctd\u003eTypical structure for strategic acquisitions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample Acquisition Equity Split\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e70%\u003c\/strong\u003e Acquired \/ \u003cstrong\u003e30%\u003c\/strong\u003e Retained\u003c\/td\u003e\n\u003ctd\u003eExample transaction structure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample Acquisition Equity Split\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e80%\u003c\/strong\u003e Acquired \/ \u003cstrong\u003e20%\u003c\/strong\u003e Retained\u003c\/td\u003e\n\u003ctd\u003eExample transaction structure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eUSPH acquisition activity demonstrating pipeline strength:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAcquired 20 de novo or aqua novo facilities through October 2024.\u003c\/li\u003e\n\u003cli\u003eAdded 103 clinics since April 1, 2024, through March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eCompleted more than 50 acquisitions since 2005.\u003c\/li\u003e\n\u003cli\u003eRecent acquisition of Metro Physical Therapy for $75 million.\u003c\/li\u003e\n\u003cli\u003eAcquisition of two practices (October 2023) for a combined $13.9 million generating $7.2 million in combined annual revenues.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e6. Financial Resilience and Shareholder Commitment\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable investment profile, evidenced by a 15-year dividend growth streak and the recent authorization of up to $25 million for share repurchases.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare. Maintaining dividend growth through regulatory cycles is a sign of strong underlying cash flow generation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Competitors can initiate buybacks, but replicating a 15-year streak requires long-term commitment and consistent cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The capital allocation strategy balances growth investment (acquisitions) with returning capital to shareholders.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While strong now, a sustained downturn could force a dividend pause, breaking the streak. Ongoing industry risks include Medicare pricing trends and reimbursement volatility.\u003c\/p\u003e\n\n\u003cp\u003eThe commitment to shareholder returns is quantified through consistent dividend increases and recent capital deployment authorization:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Dividend Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.80\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest Quarterly Dividend Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.45\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Yield (TTM)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.39%\u003c\/strong\u003e to \u003cstrong\u003e2.51%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Payout Ratio (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e73.17%\u003c\/strong\u003e to \u003cstrong\u003e75.75%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDividend Growth Years (Historical)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e15 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare Repurchase Authorization\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$25 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey statistics supporting the financial resilience assessment include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe earliest covered dividend in the database dates back to \u003cstrong\u003e03\/11\/2011\u003c\/strong\u003e, supporting the multi-year streak claim.\u003c\/li\u003e\n\u003cli\u003eThe company increased its dividend 6 times in the past 5 years.\u003c\/li\u003e\n\u003cli\u003eThe 5-Year Average Dividends Per Share Growth Rate is reported as 5.15%.\u003c\/li\u003e\n\u003cli\u003eThe most recent announced dividend amount was \u003cstrong\u003e$0.450\u003c\/strong\u003e per share, with an ex-dividend date of \u003cstrong\u003eNov 17, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected earnings by 2028 are $52.5 million, up from the current $34.6 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e7. Diversification into Higher-Reimbursement Home Care\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Expands the total addressable market and taps into services with potentially better net rates than traditional outpatient settings, as seen with the April 2025 acquisition via subsidiary Metro.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe acquired outpatient home care practice, through 50%-owned subsidiary MSO Metro, LLC, currently generates approximately \u003cstrong\u003e$2.1 million\u003c\/strong\u003e in annual revenues.\u003c\/li\u003e\n\u003cli\u003eUSPH's total physical therapy revenue for Q1 2025 was \u003cstrong\u003e$156.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Metro acquisition contributed approximately \u003cstrong\u003e$17 million\u003c\/strong\u003e in revenue to Q1 2025 results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAcquired Home Care Practice (Annualized)\u003c\/th\u003e\n\u003cth\u003eUSPH Outpatient Base (Q1 2025 Context)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$156.4 million\u003c\/strong\u003e (PT Revenue Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOwnership Stake\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e80%\u003c\/strong\u003e (Metro's interest)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50%\u003c\/strong\u003e (Metro's ownership by USPH)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal USPH Clinics (Feb 28, 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e773\u003c\/strong\u003e clinics in \u003cstrong\u003e44\u003c\/strong\u003e states\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many PT companies are exploring this, USPH is actively executing on it through a subsidiary structure.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMetro acquired an \u003cstrong\u003e80%\u003c\/strong\u003e interest in the acquired company, with existing owners retaining a \u003cstrong\u003e20%\u003c\/strong\u003e ownership interest.\u003c\/li\u003e\n\u003cli\u003ePrior to this, MSO Metro managed \u003cstrong\u003e50\u003c\/strong\u003e outpatient clinics and provided in-home physical therapy services.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The infrastructure and licensing required to enter new service lines like home care are hurdles for pure-play outpatient firms.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good. It shows management is looking beyond core outpatient to capture evolving patient demand for convenient care.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eUSPH reported a $20 million impact from Medicare rate cuts in Q1 2025, indicating the financial pressure in traditional settings that diversification seeks to mitigate.\u003c\/li\u003e\n\u003cli\u003eUSPH's Board of Directors declared a quarterly dividend of \u003cstrong\u003e$0.45\u003c\/strong\u003e per share payable on June 13, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It's a smart tactical move, but not yet a dominant, industry-defining capability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e8. Expertise in Navigating Regulatory Headwinds\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The management team successfully offset an estimated \u003cstrong\u003e$25 million\u003c\/strong\u003e in annualized earnings impact from Medicare rate cuts through operational levers in \u003cstrong\u003e2025\u003c\/strong\u003e. This signals deep knowledge of reimbursement nuances.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Few operators can absorb such a large, mandated revenue hit and still post double-digit EBITDA growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. This expertise is embedded in the senior leadership's experience navigating years of reimbursement changes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Very strong. The ability to pivot cost structures quickly is a direct result of organizational preparedness.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Regulatory navigation is a permanent feature of U.S. healthcare; this experience is invaluable.\u003c\/p\u003e\n\n\u003cp\u003eThe resilience demonstrated against federal reimbursement pressure is quantified by the following financial outcomes and management expectations:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Medicare Reimbursement Cuts\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExceeding \u003cstrong\u003e11%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected 2025 Medicare Rate Reduction Impact (EBITDA)\u003c\/td\u003e\n\u003ctd\u003eFull Year \u003cstrong\u003e2025\u003c\/strong\u003e (Expected)\u003c\/td\u003e\n\u003ctd\u003eReduction of approximately \u003cstrong\u003e$5.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActual 2024 Medicare Rate Reduction Impact (EBITDA)\u003c\/td\u003e\n\u003ctd\u003eFull Year \u003cstrong\u003e2024\u003c\/strong\u003e (Actualized)\u003c\/td\u003e\n\u003ctd\u003eReduction of approximately \u003cstrong\u003e$3.3 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Rate Per Patient Visit\u003c\/td\u003e\n\u003ctd\u003eQ3 \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$105.65\u003c\/strong\u003e (Up from \u003cstrong\u003e$102.37\u003c\/strong\u003e in Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA Guidance\u003c\/td\u003e\n\u003ctd\u003eFull Year \u003cstrong\u003e2025\u003c\/strong\u003e (Raised)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$93 million\u003c\/strong\u003e to \u003cstrong\u003e$97 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$81.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eQ3 \u003cstrong\u003e2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$197.13 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe operational levers deployed to counteract the regulatory environment include strategic pricing power and volume management, as evidenced by:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eNet rate per patient visit increasing by \u003cstrong\u003e3.2%\u003c\/strong\u003e in Q3 \u003cstrong\u003e2024\u003c\/strong\u003e despite a \u003cstrong\u003e1.8%\u003c\/strong\u003e Medicare rate reduction effective at the start of \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAverage daily patient visits per clinic reaching a record-high of \u003cstrong\u003e30.1\u003c\/strong\u003e for the third quarter of \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Industrial Injury Prevention segment posting a \u003cstrong\u003e22.6%\u003c\/strong\u003e year-over-year revenue increase.\u003c\/li\u003e\n\u003cli\u003eOperating margin improving to \u003cstrong\u003e12.6%\u003c\/strong\u003e in Q2 \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eManagement's strategy for mitigating the expected \u003cstrong\u003e$5.7 million\u003c\/strong\u003e EBITDA reduction from the \u003cstrong\u003e2.9%\u003c\/strong\u003e Medicare cut in \u003cstrong\u003e2025\u003c\/strong\u003e relies on specific, quantifiable initiatives:\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eFull-year contribution from acquisitions completed in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-year impact of commercial and other payor rate negotiations completed during \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePartial-year impact of commercial and other payor rate negotiations expected to be completed during \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eVolume increases at the Company's existing clinics.\u003c\/li\u003e\n\u003cli\u003eContinued \u003cstrong\u003edouble-digit\u003c\/strong\u003e growth initiatives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eU.S. Physical Therapy, Inc. (USPH) - VRIO Analysis: \u003cstrong\u003e9. Industrial Injury Prevention (IIP) Segment Growth Engine\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This segment is a high-growth area, with Industrial Injury Prevention (IIP) revenue increasing \u003cstrong\u003e28.8%\u003c\/strong\u003e in Q1 2025 to \u003cstrong\u003e$27.4 million\u003c\/strong\u003e, providing a counter-cyclical revenue stream less dependent on traditional insurance payors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While others offer similar services, USPH's IIP segment is clearly scaled and growing at a much faster clip than the core business. In Q3 2025, IIP net revenues increased \u003cstrong\u003e14.6%\u003c\/strong\u003e, which was all organic growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Building the necessary on-site service contracts and ergonomic expertise takes time and specialized sales talent.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. Management is clearly prioritizing and investing in this area, which is reflected in its outsized revenue growth. The IIP segment gross profit margin remained stable at \u003cstrong\u003e20.4%\u003c\/strong\u003e in Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It's a current growth driver, but its sustained advantage depends on maintaining its lead in securing large corporate contracts.\u003c\/p\u003e\n\u003cp\u003eKey Statistical and Financial Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIIP Gross Profit in Q1 2025 was \u003cstrong\u003e$5.6 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e29.1%\u003c\/strong\u003e year-over-year.\u003c\/li\u003e\n\u003cli\u003eTotal patient visits in Q1 2025 surged \u003cstrong\u003e13.9%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e1,443,805\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet revenue per patient visit for Q1 2025 was \u003cstrong\u003e$105.66\u003c\/strong\u003e, an increase of \u003cstrong\u003e$2.29\u003c\/strong\u003e per visit from Q1 2024, despite a \u003cstrong\u003e2.9%\u003c\/strong\u003e Medicare rate reduction.\u003c\/li\u003e\n\u003cli\u003eTotal owned and\/or managed clinic count was \u003cstrong\u003e773\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSegment Performance Comparison:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eIIP Segment (Q1 2025)\u003c\/td\u003e\n\u003ctd\u003ePhysical Therapy Operations (Q1 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$156.4 million\u003c\/strong\u003e (Total Revenue)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16.4%\u003c\/strong\u003e (Total Revenue)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e20.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16.3%\u003c\/strong\u003e (Gross Profit Margin)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The draft 13-week cash flow forecast incorporating the Q3 \u003cstrong\u003e$23.9 million\u003c\/strong\u003e Adjusted EBITDA and the authorized \u003cstrong\u003e$25 million\u003c\/strong\u003e buyback plan is required by Friday.\u003c\/p\u003e\n\u003cp\u003eQ3 2025 Adjusted EBITDA was reported at \u003cstrong\u003e$23.9 million\u003c\/strong\u003e, representing a \u003cstrong\u003e13.2%\u003c\/strong\u003e increase from Q3 2024's \u003cstrong\u003e$21.1 million\u003c\/strong\u003e. The Board of Directors declared a quarterly dividend of \u003cstrong\u003e$0.45\u003c\/strong\u003e per share payable on December 12, 2025.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516274040981,"sku":"usph-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/usph-vrio-analysis.png?v=1740226103","url":"https:\/\/dcf-model.com\/pt\/products\/usph-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}